Results for Clinical Vector Production

Share:
1 - 10 of 29
Stefano Rivella, PhD
Stefano Rivella

Dr. Rivella is an expert in the pathophysiology of erythroid and iron disorders and in the generation of lentiviral vectors for the cure of hemoglobinopathies. He also investigates additional disorders such as anemia of inflammation and hemochromatosis.

E-mail:
rivellas [at] chop.edu
Laura Breda, PhD
Laura Breda

Dr. Breda is developing safe, potentially curative genetic therapies for sickle cell disease and b-thalassemia.

E-mail:
bredal [at] chop.edu

Optimizing Vector Delivery to Reduce Risk: Q&A With Beverly Davidson, PhD, and Misun Hwang, MD

Published on
Feb 6, 2023
in Cornerstone Blog
Gene Therapy and Radiology Team Up to Optimize Vector Delivery
Two scientists with unique skill sets are developing an alternative method for gene therapy delivery with support from a CGTC Seed Grant.

In the News: Dr. Susan Furth, Clinical Vector Core, Mito Model, Immunotherapy

Published on
Nov 11, 2022
in Cornerstone Blog
In the News
This week’s research news roundup includes accolades for our scientists and the spaces they work in.

Katherine High, MD, Awarded Esteemed CHOP Gold Medal

Published on
May 12, 2022
in Cornerstone Blog
Katherine High, MD, Awarded Esteemed CHOP Gold Medal
CHOP recognized gene therapy pioneer, Katherine High, MD, with Children’s Hospital of Philadelphia’s Gold Medal Award.

Research Shows Multiyear Factor VIII Expression After Hemophilia A Gene Therapy

Published on
Nov 19, 2021
in Cornerstone Blog
A one-time treatment with an adeno-associated viral vector demonstrated safe, sustained factor VIII expression for patients with hemophilia A.
Dr. Lindsey George and colleagues report safe and sustained expression following hemophilia A gene therapy.

Where Discovery Leads: Building on Nature's Delivery System to Advance Gene Therapy

Published on
Nov 5, 2021
in Cornerstone Blog
Raymond G. Perelman Center for Cellular and Molecular Therapeutics
The Clinical Vector Core, an award-winning, state-of-the-art, multi-product GMP manufacturing facility, supports the growing field of gene therapy.

In the News: CCMT Facility Honored, Autistic Drivers, Predicting EoE Milk Allergy, Minority Trainee Development Scholarship, PAS Preview

Published on
Apr 30, 2021
in Cornerstone Blog
In the News
This week’s news round-up highlights the CCMT’s state-of-the-art Clinical Manufacturing Facility

Snapshot Science: Will a New Vector Offer Safer Gene Therapy for Red Blood Disorders?

Published on
Feb 1, 2021
in Cornerstone Blog
Snapshot Science: Will a New Vector Offer Safer Gene Therapy for Red Blood Disorders?
CHOP researchers have developed a potentially safer and more effective gene therapy vector for red blood disorders.

Looking Ahead to a Vaccine for the Coronavirus: Q&A With Paul Offit, MD

Published on
Dec 21, 2020
in Cornerstone Blog
Looking Ahead to a Vaccine for the Coronavirus: Q&A With Paul Offit, MD
Paul Offit, MD, director of the Vaccine Education Center, and a world-renowned vaccine expert, discusses the pending genetic vaccines for COVID-19.
1 - 10 of 29